Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 9,512 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00983437
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
61
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 16, 2026, 5:48 PM EDT
Terminated No phase listed Observational Results available

Prospective Study to Evaluate Outcomes From Transoral BOT Resection for OSAHS

NCT01107795
View directory record Official record
Conditions
Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)
Interventions
Transoral Robotic Surgery
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

NCT01952080
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
1 Year to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

NCT02032888
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Sofosbuvir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Beverly Hills, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 16, 2026, 5:48 PM EDT
Available No phase listed Expanded access

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

NCT05572970
View directory record Official record
Conditions
Cancer
Interventions
Balstilimab, Zalifrelimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
U.S. locations
7
States / cities
Birmingham, Alabama • Tucson, Arizona • Newport Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 16, 2026, 5:48 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

The Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis

NCT07250854
View directory record Official record
Conditions
Biliary Atresia, Kasai, Cholestasis in Newborn, Cholestasis in Newborn Infant
Interventions
Indocyanine Green
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
2 Weeks to 4 Months
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 16, 2026, 5:48 PM EDT
Active, not recruiting Phase 2 Interventional

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

NCT05676931
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development of an Adaptive Treatment for Weight Loss in People With Prediabetes

NCT04745572
View directory record Official record
Conditions
PreDiabetes, Obesity
Interventions
High Carbohydrate Diet, Reduced Carbohydrate Diet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis

NCT04769596
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
NEUROMARK™ System, Sham Device
Device
Lead sponsor
Neurent Medical
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Roseville, California • Colorado Springs, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 16, 2026, 5:48 PM EDT
Recruiting No phase listed Observational

Impact of Gut Microbiome on Metabolic and Bowel Function During the First Year After Spinal Cord Injury

NCT05670288
View directory record Official record
Conditions
Spinal Cord Injuries, Gut Microbiome
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension

NCT00644605
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
sildenafil, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
24
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of Ataluren (PTC124) in Cystic Fibrosis

NCT01140451
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 16, 2026, 5:48 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT07645924
View directory record Official record
Conditions
Migraine
Interventions
Elismetrep, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
113
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 5:48 PM EDT
Terminated Phase 1 Interventional

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

NCT03144661
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer, Ovarian Cancer, Solid Tumors
Interventions
INCB062079
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • New York, New York • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes Mellitus

NCT00212641
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
ONO-5129
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
67
States / cities
Birmingham, Alabama • Calera, Alabama • Huntsville, Alabama + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

NCT00244751
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
GI262570 0.5 mg, GI262570 1.0 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 70 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

NCT00335153
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

NCT01654796
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Low Field Magnetic Stimulation (LFMS), Sham LFMS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Longitudinal Study of Dental Implant Therapy in HIV Positive Patients

NCT01211288
View directory record Official record
Conditions
Dental Implant
Interventions
Astra implants
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

NCT00612742
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
50 Years and older · Female only
Enrollment
3,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
141
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 16, 2026, 5:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes

NCT06353256
View directory record Official record
Conditions
Preeclampsia Postpartum, Adverse Pregnancy Outcomes
Interventions
usual postpartum care, usual postpartum care + community health worker intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 56 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 16, 2026, 5:48 PM EDT
Active, not recruiting Phase 3 Interventional

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

NCT05611931
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Selinexor, Matching Placebo for selinexor
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 16, 2026, 5:48 PM EDT
Not listed No phase listed Observational

Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995

NCT02082353
View directory record Official record
Conditions
Granulomatous Disease, Chronic
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 16, 2026, 5:48 PM EDT